Aurinia Pharmaceuticals/$AUPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Ticker
$AUPH
Sector
Primary listing
Employees
130
Headquarters
Edmonton, Canada
Website
AUPH Metrics
BasicAdvanced
$1.5B
26.93
$0.42
1.27
-
Price and volume
Market cap
$1.5B
Beta
1.27
52-week high
$13.54
52-week low
$6.55
Average daily volume
1.8M
Financial strength
Current ratio
5.225
Quick ratio
4.539
Long term debt to equity
19.271
Total debt to equity
24.405
Interest coverage (TTM)
13.91%
Profitability
EBITDA (TTM)
82.582
Gross margin (TTM)
80.16%
Net profit margin (TTM)
23.31%
Operating margin (TTM)
24.26%
Effective tax rate (TTM)
2.96%
Revenue per employee (TTM)
$2,000,000
Management effectiveness
Return on assets (TTM)
7.69%
Return on equity (TTM)
17.33%
Valuation
Price to earnings (TTM)
26.93
Price to revenue (TTM)
6.082
Price to book
4.48
Price to tangible book (TTM)
4.53
Price to free cash flow (TTM)
17.115
Free cash flow yield (TTM)
5.84%
Free cash flow per share (TTM)
0.661
Growth
Revenue change (TTM)
25.59%
Earnings per share change (TTM)
-219.83%
3-year revenue growth (CAGR)
43.57%
10-year revenue growth (CAGR)
99.46%
3-year earnings per share growth (CAGR)
-28.49%
10-year earnings per share growth (CAGR)
0.25%
What the Analysts think about AUPH
Analyst ratings (Buy, Hold, Sell) for Aurinia Pharmaceuticals stock.
Bulls say / Bears say
Net product sales of LUPKYNIS reached $66.6 million in Q2 2025, a 21% year-over-year increase driven by broader guideline adoption and deeper penetration into the lupus nephritis market (Nasdaq).
Aurinia delivered GAAP net income of $21.5 million in Q2 2025 versus $0.7 million in Q2 2024 and generated $45.5 million of operating cash flow in the first half of 2025 (or $57.0 million excluding restructuring charges), underscoring improved profitability post-restructuring (Nasdaq).
AUR200’s Phase 1 single-ascending-dose data showed robust, sustained immunoglobulin reductions of up to 55% and a strong safety profile, supporting plans to initiate Phase 2 studies in multiple autoimmune indications in H2 2025 (Nasdaq).
Reddy’s, Sandoz and other generic drugmakers have submitted Paragraph IV ANDAs challenging Aurinia’s LUPKYNIS patents expiring in December 2037, prompting the company to file multiple infringement lawsuits and exposing it to material litigation risk (SEC 10-Q).
Inventory levels rose 19% to $46.5 million at June 30, 2025, up from $39.2 million at December 31, 2024, which may point to demand forecasting or supply chain inefficiencies that could pressure margins (Nasdaq).
Roche’s Gazyva® (obinutuzumab) supplemental BLA for lupus nephritis was accepted by the FDA with a PDUFA target of October 2025, potentially introducing a well-capitalized competitor into Aurinia’s core market (Roche)).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
AUPH Financial Performance
Revenues and expenses
AUPH Earnings Performance
Company profitability
AUPH News
AllArticlesVideos
Aurinia Responds to Now Retracted LinkedIn Post
Business Wire1 week ago
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
Business Wire2 months ago
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aurinia Pharmaceuticals stock?
Aurinia Pharmaceuticals (AUPH) has a market cap of $1.5B as of October 08, 2025.
What is the P/E ratio for Aurinia Pharmaceuticals stock?
The price to earnings (P/E) ratio for Aurinia Pharmaceuticals (AUPH) stock is 26.93 as of October 08, 2025.
Does Aurinia Pharmaceuticals stock pay dividends?
No, Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders as of October 08, 2025.
When is the next Aurinia Pharmaceuticals dividend payment date?
Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals (AUPH) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.